Hemogenyx Pharmaceuticals Overview

  • Founded
  • 2013
Founded
  • Status
  • Public
  • Employees
  • 7
Employees
  • Stock Symbol
  • HEMO
Stock Symbol
  • Investments
  • 1
  • Share Price
  • $0.02
  • (As of Tuesday Closing)

Hemogenyx Pharmaceuticals General Information

Description

Hemogenyx Pharmaceuticals PLC and its subsidiary is a preclinical-stage biotechnology company focused on the discovery, development, and commercialization of novel therapies and treatments for blood diseases, like leukemia and lymphoma. The company's technologies aim to change the way in which bone marrow/hematopoietic stem cell transplants are performed and improve their efficacy. Its two distinct products include an immunotherapy product for patient conditioning, the CDX bi-specific antibody, and a cell therapy product for BM/HSC transplantation, the HuPHEC.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly Accelerator/Incubator backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Stock Exchange
LON
Primary Office
  • 5 Fleet Place
  • London EC4M 7RD
  • England, United Kingdom
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Hemogenyx Pharmaceuticals Stock Performance

(As of Tuesday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$0.02 $0.02 $0.02 - $0.12 $23.4M 980M 8.09M -$0.01

Hemogenyx Pharmaceuticals Financials Summary

In Thousands,
USD
TTM 30-Jun-2021 FY 2020 31-Dec-2020 FY 2019 31-Dec-2019 FY 2018 31-Dec-2018
EV 30,984 55,044 9,343 7,973
Revenue 0 0 0 0
EBITDA (2,846) (2,510) (1,756) (2,052)
Net Income (6,563) (2,669) (1,851) (2,059)
Total Assets 15,371 3,631 1,377 2,918
Total Debt 2,123 2,219 1,648 1,488
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Hemogenyx Pharmaceuticals Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Hemogenyx Pharmaceuticals‘s full profile, request access.

Request a free trial

Hemogenyx Pharmaceuticals Executive Team (3)

Name Title Board Seat Contact Info
Vladislav Sandler Ph.D Chief Executive Officer & Board Member
Andrew Wright Executive & Secretary, Administration
You’re viewing 2 of 3 executive team members. Get the full list »

Hemogenyx Pharmaceuticals Board Members (5)

Name Representing Role Since
Alexis Sandler JD Hemogenyx Pharmaceuticals Board Member 000 0000
Marc Feldmann Hemogenyx Pharmaceuticals Chairman & Board Member 000 0000
Peter Redmond Hemogenyx Pharmaceuticals Board Member 000 0000
Vladislav Sandler Ph.D Hemogenyx Pharmaceuticals Chief Executive Officer & Board Member 000 0000
You’re viewing 4 of 5 board members. Get the full list »

Hemogenyx Pharmaceuticals Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Hemogenyx Pharmaceuticals Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Hemogenyx Pharmaceuticals‘s full profile, request access.

Request a free trial

Hemogenyx Pharmaceuticals Acquisitions (1)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
000000 000000 08-Oct-2017 0000000000 Holding Companies 000000000
To view Hemogenyx Pharmaceuticals’s complete acquisitions history, request access »